Eli Lilly, TPG-Axon Capital Management L.P., Quintiles deal

TPG-Axon and Quintiles’ NovaQuest unit will provide Lilly about $300 million for Phase III trials of the gamma secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzh...